Skip to content

Total Equity at other companies

Eli Lilly logo
Eli LillyLLY
$31.2B+97.9%
Amgen logo
AmgenAMGN
$9.19B+48.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Janux Therapeutics logo
Janux TherapeuticsJANX
$941.54M-7.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$576.22M+4,094%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+140%
Enterprise value$1.01B+168%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s total equity?
Cullinan Therapeutics, Inc. (CGEM) reported total equity of $408.73M in Q4 2025.
How has Cullinan Therapeutics, Inc.'s total equity changed year-over-year?
Cullinan Therapeutics, Inc.'s total equity decreased by 30.8% year-over-year, from $590.33M to $408.73M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s total equity has grown at a 15.5% compound annual growth rate (CAGR), from $199.01M to $408.73M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.